AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00063362
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Trial: NCT00063362
Drug: Divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
Trial: NCT04082325
Drug: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
RxNorm normalized name: spike lavender oil
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT04082325
Drug: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
RxNorm normalized name: spike lavender oil
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT04018950
Drug: 14C-ETX2514
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT00805311
Drug: atorvastatin, aspirin, losartan, amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
Trial: NCT04389424
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of tamoxifen for breast cancer recurrence prevention
Trial: NCT04389424
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of exemestane for breast cancer recurrence prevention
Trial: NCT04389424
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of anastrozole for breast cancer recurrence prevention
Trial: NCT03194932
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
Trial: NCT03194932
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV) or intrathecally (IT).
Trial: NCT03194932
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT03194932
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV.
Trial: NCT02174445
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib, 400 to 800 mg p.o., daily
Trial: NCT02174445
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg p.o., twice-daily
Trial: NCT04179656
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg administered orally, once daily, continuously in 21 day cycles
Trial: NCT01655069
Drug: Solifenacin succinate suspension
RxNorm normalized name: solifenacin succinate Oral Suspension
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT00920270
Drug: nebulized colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebulized colistin 75 mg every 12 hours
Trial: NCT00298545
Drug: placebo and Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
Trial: NCT03254641
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IE times one
Trial: NCT04207385
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
Trial: NCT00050843
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03680508
Drug: TSR-022 and TSR-042
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: immunotherapy
Trial: NCT00494988
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00004489
Drug: alendronate sodium
RxNorm normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004489
Drug: calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004489
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03874858
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib oral 300 mg QD hard capsules
Trial: NCT03874858
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib oral 300 mg BID hard capsules
Trial: NCT03874858
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
Trial: NCT02060188
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT02060188
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT02060188
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02060188
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT02060188
Drug: BMS-986016
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06641440
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be treated for three months in the two groups with the two different protocols for three months both
Trial: NCT04135352
Drug: 200 mg of pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
Trial: NCT03258190
Drug: Lime Powder Regimen
RxNorm normalized name: Lime
DrugBank: Lime (citrus) (DB10635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPR and placebo were randomly given to subjects for 6 months
Trial: NCT03031730
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03031730
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03031730
Drug: Dexamethasone Sodium Phosphate
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03031730
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03031730
Drug: Navtemadlin
RxNorm normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01941628
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
Trial: NCT01941628
Drug: Succinylcholine
RxNorm normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
Trial: NCT02951156
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating drug
Trial: NCT02951156
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nucleoside analogue
Trial: NCT02951156
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Platinum-based drug
Trial: NCT00176254
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 225 mg/m2 intravenously over three hours on Days 1 and 22
Trial: NCT00176254
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
Trial: NCT01647256
Drug: Nikkomycin Z
RxNorm normalized name: Nikkomycin Z
DrugBank: Nikkomycin Z (DB12939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 500 mg, single-dose
Trial: NCT02240199
Drug: Intraoperative Intravenous Lidocaine Infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Trial: NCT02240199
Drug: Perioperative Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Trial: NCT02240199
Drug: Perioperative Pregabalin Placebo
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Trial: NCT02240199
Drug: Intraoperative Intravenous Lidocaine Placebo Infusion
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Trial: NCT01603459
Drug: IncobotulinumtoxinA
RxNorm normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection.
Trial: NCT01428453
Drug: 250mg rilapladib
RxNorm normalized name: Rilapladib
DrugBank: Rilapladib (DB05119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Drug
Trial: NCT00399360
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
Trial: NCT02536339
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trial: NCT02536339
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trial: NCT03019939
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO or IV
Trial: NCT03301038
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
Trial: NCT02626520
Drug: Gemcitabine and nanoparticle albumin bound paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
Trial: NCT00028288
Drug: Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00972257
Drug: treatment with dorzolamide/timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-hour IOP control with the two fixed combinations
Trial: NCT00972257
Drug: treatment with brimonidine/timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-hour pressure control with brimonidine/timolol
Trial: NCT01157429
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
Trial: NCT04231565
Drug: Tenofovir alafenamide Fumarate
RxNorm normalized name: Tenofovir Alafenamide fumarate
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
Trial: NCT02099591
Drug: Naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Opioid Antagonist
Trial: NCT02620865
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02620865
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02620865
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02620865
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02571855
Drug: ACT-541468 (hydrochloride salt)
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hard-gelatin capsules (strength: 5 mg and 25 mg)
Trial: NCT02571855
Drug: ACT-541468 (free base)
RxNorm normalized name: Amlodipine free base
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soft capsules (strength: 25 mg)
Trial: NCT03838328
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
Trial: NCT04081012
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
Trial: NCT02605616
Drug: AZ compound
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
Trial: NCT01724385
Drug: intravitreal injection of bevacizumab
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of bevacizumab
Trial: NCT03755154
Drug: S65487- initial scheme
RxNorm normalized name: brigatinib
DrugBank: S65487 (DB17556)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
Trial: NCT03755154
Drug: S65487 - alternative scheme
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: S65487 (DB17556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
Trial: NCT03882801
Drug: Gefapixant
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
Trial: NCT02469961
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
Trial: NCT02469961
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
Trial: NCT00504556
Drug: Edoxaban (DU-176b)
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30mg tablet once daily
Trial: NCT00504556
Drug: Edoxaban (DU-176b)
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60mg tablet once daily
Trial: NCT00504556
Drug: Edoxaban (DU-176b)
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30mg tablet two times a day
Trial: NCT00504556
Drug: Edoxaban (DU-176b)
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60mg tablet two times a day
Trial: NCT00504556
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: warfarin tablets
Trial: NCT01125644
Drug: SPK-843
RxNorm normalized name: SPK-3006
DrugBank: Vanglusagene ensiparvovec (DB17675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
Trial: NCT01978015
Drug: travoprost and timolol maleate fixed combination
RxNorm normalized name: Timolol Maleate
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
Trial: NCT01978015
Drug: latanoprost and maleate timolol fixed combination
RxNorm normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
Trial: NCT01978015
Drug: bimatoprost and timolol maleate fixed combination
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
Trial: NCT01978015
Drug: dextran and hypromellose
RxNorm normalized name: dextran 70 / hypromellose
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
Trial: NCT01267136
Drug: Tramadol suspension
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
Trial: NCT02078609
Drug: LGH447 + midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LGH447 + midostaurin in patients with AML
Trial: NCT00101400
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg administered twice daily (b.i.d.)